And, although I’m not at SABCS this year, why do we not have data on TILS from KN522?!

Not at SABCS, but from afar there has to be some positive biomarkers from a trial where a significant minority don’t seem to benefit (in terms of pathCR at least) from treatment. More work needed!

The hallmarks of cancer immune evasion Cancer cells often evade the host immune system, challenging the effectiveness of immunotherapy. In this comprehensive review, Galassi et al. summarize key mechanisms of immune evasion within the “thr...

The hallmarks of cancer immune evasion

We have an open #PhD #studentship as part of our "Black Leaders in Cancer" programme at @crukconvergence.bsky.social & @icrlondon.bsky.social. About computational modelling of T-cell evolution in cancer. www.findaphd.com/phds/project... I'm looking forward to meeting prospective students #CRUKfunded

I should also add that regulators have a key role here and there are signs that requirements will change. We need to using prognostic biomarkers (eg path response) and balancing the harm versus benefit of these treatments for both patients and health care systems

Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.

The SONIA trial shows the utility of well-designed academic trials. But funding such studies is getting harder and harder. We need to work with industry to design smarter trials that don’t need further costly and lengthy trials to fill gaps www.nature.com/articles/d41... @oncoalert.bsky.social #bcsm

This is potentially very interesting data but follow up is short at this point and would want to see an EFS/OS outcome. Does provide early signal and could be useful for those where steroids are contraindicated or problematic

Same comment as on the other forum!

I really like this paper and remember being impresssed when it was presented. Hats off to the authors!

It’s the best CME there is. Shame you can’t claim the time!

Certainly needs unpicking and hopefully the samples exist to do that. Did the trial contain a cytotoxic back bone? If not, I wonder if this is needed. Seemingly lots of potential but so far a complex story with anti-TIGIT molecules

⏰ Final call!

🧑‍🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester

To apply (deadline 1 Dec 2024):
www.cruk.manchester.ac.uk/recruitment/...

I’m at 2 rejections for what we feel is a practice changing study. One likely ‘out of scope’, 2nd too expensive and not enough evidence of community support (multiple surveys/patient focus groups backing). Hopeful plan c being made today but it is quite exhausting!

Feel your pain. Can feel like a brick wall. But, celebrate your (very obvious) successes and remember you’re doing great and your research will make a difference!

Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles

I’ll await my invite..

Not attending this year sadly!

Feel free to please add me Mike

Indeed, also not without controversy I think due to AI results but more relevant than ever due to ⬆️ use. However, I’ve seen critiques of the adherence in the trial and ⬆️vaginal oestrogen doses used that are much higher than modern preparations. Always ➕/➖ when discussing with pts

Yep quoting to keep the links!

Reassuring BUT short follow up at this time point

Bravo, great paper. Lots of emerging data for the PD1/TIGIT combo in the lab but data from lung trials has been disappointing. I hope that new strategies, with chemo or ADC backbones, may help circumvent this resistance. We know cytotoxics induce CSCs and it needs exploring

Interesting results, be nice to see these replicated in other eTNBC IO trials. Also to explore links with irAEs

ALSPAC in Bristol?

@ptarantinomd.bsky.social? ☝️

Anecdotally, seeing an awful lot of younger patients with TNBC coming through MDT. Is anyone else seeing this?

Every. Single. Time

I’m excited to see data at #SABCS but I’m also mindful that we are adding more and more to treatments and feel like we’re reaching the point that we need to start trying smarter patient selection to prevent harm @oncoalert.bsky.social #oncsky

✋

#oncsky